We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Second Tier Cities in China Could Provide Medical Market Opportunities

By HospiMedica International staff writers
Posted on 31 Oct 2011
Companies marketing pharmaceuticals, medical devices, and diagnostic products may find that their best growth opportunities lie in China’s second tier cities. These are the latest findings of Kalorama Information (New York, NY, USA), an independent market research firm.

While major urban healthcare markets, concentrated around metropolises like Shanghai, Hong Kong, Beijing, and Guangzhou, have long featured high demand for a range of pharmaceutical and medical devices, pronounced urbanization throughout China has nurtured demand in smaller cities along China’s coastal provinces, and also in the middle and western half of the giant country. The provinces of Southwestern and Central China are projected to see the greatest market growth for pharmaceuticals and medical devices over the next four years, with strong demand out of their emerging regional metropolises.

Economic development in Chinese cities and urban migration have resulted in the percentage of Chinese residing in urban healthcare markets rising from 36% in the year 2000 to 50% in 2010, a rise that continues to bolster the urban healthcare market. Rural residents living in these areas are also apt to pursue specialty outpatient and inpatient care at city hospitals. As a result, the current urban healthcare market in China (including Hong Kong) is over three times the size of the rural healthcare market, with a market volume of approximately US$183.2 billion.

“Cities like Chengdu, Chongqing in West China, and Zhengzhou and Wuhan in Central China are already the beneficiaries of multinational companies’ research and development investment,” said Kalorama Information research analyst Emil Salazar. “But they are also targets for medical product sales and ideal hubs for provincial and regional distribution networks for pharmaceuticals, IVD reagents, and other medical supplies.”

Kalorama Information notes, however, that even with the Chinese governments apparent priorities in improving rural healthcare, recently expanded national health plans provide over five times more total reimbursements to urban enrollees than to rural enrollees. Despite this disparity, the Chinese government must still manage and fund even more diversified and expensive urban healthcare systems, which are equally beset by challenges in coverage.

Related Links:
Kalorama Information





Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Hospital Bed
Alphalite
New
Fetal and Maternal Monitor
F9 Series

Latest Business News

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024

Boston Scientific to Acquire AFib Ablation Company Cortex